Every vendor catalogue now has a blends section: BPC-157/TB-500 in one vial, CJC-1295/ipamorelin in another, four-peptide skin blends beside them. The pitch is obvious — fewer vials, fewer injections, one reconstitution, usually a lower price per milligram. The pitch is also mostly true. The question is narrower than are blends good, and it has a clean answer.
A blend locks you into its ratio. The component peptides frequently want different schedules. Those two facts collide.
This article is about the buying decision itself. If you have already bought a blend and need to work out what a given syringe mark delivers, that’s peptide blend dosing math. If you want to know which specific products are worth attention, see Glow and Klow blends. If you are considering drawing two separate peptides into one syringe yourself, the compatibility question lives in mixing peptides in one syringe.
The ratio problem, concretely
Take the most-sold blend on the market: 6mg BPC-157 + 6mg TB-500 in a single vial. A tidy 1:1. Now look at how those two compounds are actually run.
BPC-157 is a small, fast-clearing peptide typically run every day. TB-500 is run in multi-milligram hits a couple of times a week. The doses differ by roughly an order of magnitude and the frequencies differ by a factor of three or more. A fixed 1:1 vial has to serve both, and it cannot.
Work it through. In a 1:1 blend, every microgram of BPC-157 you draw comes with a microgram of TB-500.
- Dose it for BPC-157. You want 500mcg daily. That draw also delivers 500mcg of TB-500 — call it 3.5mg a week against a typical 4-10mg. You are low, and you are trickling a compound whose whole design is intermittent loading.
- Dose it for TB-500. You want 2.5mg twice weekly. Each of those draws also delivers 2.5mg of BPC-157 — five times a typical daily dose, twice a week, and nothing on the other five days. You have overshot one compound and turned a daily peptide into a twice-weekly one.
Milligrams per week of each component, depending on which compound you dose the blend for. The typical target for each is shown for comparison.
The weekly totals look almost reasonable, which is exactly why this slips past people. The problem isn’t the weekly milligram count — it’s the shape. Dosing for TB-500 gives you two enormous BPC-157 spikes and five empty days, from a peptide with a short half-life whose entire rationale is continuous presence. The area under the curve is not the protocol.
What blends genuinely buy you
The case for blends is real and it deserves better than a strawman.
- Fewer injections. Two compounds, one stick. Over an eight-week run that’s a meaningful reduction in tissue trauma and in the number of chances to get something wrong.
- Less handling. One vial to reconstitute, one to store, one to draw from. Every additional handling step is an additional opportunity for contamination or a maths error.
- One reconstitution. No juggling two different bacteriostatic-water volumes and two concentrations in your head at 6am.
- Often cheaper per milligram. Blends are frequently priced below the sum of their parts.
- Someone already solved compatibility. This is the underrated one. A formulator lyophilising two peptides together has committed to their stability in the same buffer at the same pH. You get that answer for free instead of guessing at it yourself.
What you give up
- Ratio flexibility. The ratio is set at manufacture. You cannot change it. This is the whole article.
- Titration of one component. If TB-500 is fine but BPC-157 is giving you a heavy, sluggish feeling, you cannot back off one without backing off both.
- Attribution. Something happens — good or bad — and you have no way to tell which compound caused it, because you introduced them simultaneously and you cannot separate them now. This is the same trap covered in running one peptide at a time, except a blend makes it structural rather than a choice.
- Independent stopping. Want to run BPC-157 for another month after the TB-500 phase is done? Buy another vial.
When blends are the right buy
The rule falls out of the ratio test: a blend works when both compounds are dosed together anyway, at the same frequency, in a ratio that suits both.
CJC-1295 (no DAC) + ipamorelin is the strong case. A GHRH analog and a GHRP, both dosed 1-3 times daily, both timed to the same fasted windows, both wanted in the same session because the synergy is the co-administration. A 2:1 or 1:1 blend at roughly 100mcg CJC / 100-200mcg ipamorelin per dose lands squarely in the normal range for each. Nothing is compromised. Separate vials would give you two sticks and two dilutions in exchange for flexibility you were never going to use. Detail on that pairing is in the CJC-1295/ipamorelin blend.
Cosmetic and skin blends are often fine for the same reason — the components are daily, low-dose, and the ratio question is less consequential.
BPC-157/TB-500 is the weak case, despite being the best-seller. The schedules simply do not reconcile.
Before you buy: run the numbers
The mistake is buying the blend and then working out what it delivers. Do it in the other order. Take the vendor’s stated ratio and vial content, pick the dose you want for your primary compound, and calculate what the secondary compound comes along for the ride at. Our blend calculator does this — enter both peptide amounts and your bacteriostatic-water volume, and it gives you the per-unit delivery of each component. If the secondary number lands outside its normal range, that blend is not for your protocol, regardless of the price per milligram.
The arithmetic behind it — why the ratio, not the total, is what you’re buying — is worked through in peptide blend dosing math.
Frequently Asked Questions
Is a BPC-157/TB-500 blend a bad product?
Not a bad product — a mismatched one for most protocols. The compounds are genuinely complementary and the vial itself may be perfectly well made. The issue is that BPC-157 is typically run daily at 250-500mcg while TB-500 is run at 2-5mg two or three times weekly, and a fixed 1:1 ratio cannot produce both patterns from the same draw.
Are blends cheaper than buying peptides separately?
Usually yes on a per-milligram basis, and that’s a real saving. But price per milligram is the wrong metric if the ratio forces you to underdose one component or overshoot the other — you end up paying less for peptide you cannot use at the dose you wanted. Compare cost only after you have checked that the ratio fits both schedules.
Which blends are actually worth buying?
The ones where both compounds share a dosing frequency. CJC-1295 (no DAC) with ipamorelin is the clearest example: both are dosed 1-3 times daily in the same session, and standard blend ratios land in the normal range for each. Blends of compounds with mismatched schedules are the ones to think twice about.
Can I just dose a blend twice, once for each peptide?
No — every draw delivers both components in the fixed ratio, so dosing more often to satisfy the higher-frequency peptide also increases the other one proportionally. There is no draw pattern that decouples them. The only fix is a separate vial of the compound you need to control independently.
Does a blend affect peptide stability?
A properly formulated blend is lyophilised with both peptides in a compatible buffer, and the formulator has taken on that stability question — which is one of the genuine advantages over mixing two products yourself. Self-mixing two reconstituted peptides in one syringe raises separate compatibility considerations, covered in our guide to mixing peptides in one syringe.
Related reading
- Peptide Blend Dosing Math — the arithmetic once you own the vial
- Mixing Peptides in One Syringe — the self-mixing alternative and its compatibility limits
- Glow and Klow Peptide Blends — what’s actually in the popular cosmetic blends
- BPC-157 vs TB-500 — why the two compounds run on such different schedules